Chimerix

Clinical Trials

Chimerix has completed a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation multi-center trial evaluating the safety, tolerability and ability of CMX001 to prevent or control CMV disease in 230 seropositive allogeneic cell transplant recipients. Read More